Vaccine-based strategies include AADvac-1 (tau aa 294–305 conjugated to KLH), which was shown to be safe and immunogenic in a Phase I trial in mild to moderate AD, and ACI-35, a liposomal vaccine with a synthetic phospho-tau peptide (aa 393–408, pS396/pS404) that elicits strong phospho-specific antibody responses in animal models (Winblad et al. 2014). Here, MAPT is linked to Alzheimer disease.